Bild zu Biopharm

N-terminal Sequencing

Since 2001 SYMBIOSIS provides you with a variety of Automated Edman sequencing services in a GMP/GLP regulated environment:

  • Determination of the N-terminal amino acid sequence of peptides and proteins/antibodies according to ICH guideline Q6B
  • Feasibility studies and method validation of Edman sequencing assays according to ICH guideline Q2
  • Follow-up techniques such as MALDI-TOF MS and peptide mapping to generate supporting protein data on the complete sequence and the secondary structure (disulfide bridges)
  • Determination of the C-terminal amino acid sequence of proteins or antibodies by complete N-terminal sequencing of the C-terminal peptide generated by peptide mapping
  • N-terminal sequence analysis of Erythropoietin according to Ph. Eur.

Automated Edman sequencing is a key technique for characterisation and quality control of peptides and proteins:

  • As a direct sequencing technology the sequencing of not more than 10 to 15 N-terminal amino acids is usually  sufficient for the positive identification of a protein, regardless of its size or structure
  • Included in the Ph. Eur. monograph of the glycoprotein Erythropoietin
  • Essential part of characterisation and comparability  programs of antibodies

Automated Edman sequencing offers several advantages over competing mass spectrometry based sequencing technologies:

  • It clearly distinguishes between equal-mass amino acids (I/L and K/Q)
  • Provides a straightforward result traceability on the basis of HPLC chromatograms compared to the rather elaborate evaluation of complex fragmentation data

As one of the key sequencing technologies Automated Edman sequencing is a focus area within the service portfolio of SYMBIOSIS. Our expertise and techniques combined with the equipment available at SYMBIOSIS ensure highest quality in the performance and documentation of  N-Terminal sequencing to meet your specific requirements. Now and in the future.

Download our fact sheet